Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. 2001

S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
Division of Infectious Diseases, Department of Medicine, University of Maryland, School of Medicine, Baltimore, Maryland, USA.

We previously determined that the urine of interstitial cystitis (IC) patients specifically contains a factor (antiproliferative factor [APF]) that inhibits primary bladder epithelial cell proliferation, and that it has significantly decreased levels of heparin-binding epidermal growth factor-like growth factor (HB-EGF) and increased levels of epidermal growth factor (EGF) compared with urine from asymptomatic controls and patients with bacterial cystitis. We sought to confirm the specificity of these findings for IC using a larger patient population, including control patients with a variety of urogenital disorders. Clean catch urine specimens were collected from 219 symptomatic IC patients, 113 asymptomatic controls without bladder disease, and 211 patients with various urogenital diseases including acute bacterial cystitis, vulvovaginitis, chronic nonbacterial prostatitis, overactive bladder, hematuria, stress incontinence, neurogenic bladder, benign prostatic hyperplasia, bladder or pelvic pain without voiding symptoms, bladder cancer, prostate cancer, or miscellaneous diagnoses including anatomic disorders. APF activity was determined by (3)H-thymidine incorporation into primary normal adult human bladder epithelial cells. HB-EGF and EGF levels were determined by enzyme-linked immunosorbent assay. APF activity was present significantly more often in IC than control urine specimens (P <0.005 for IC vs any control group; sensitivity = 94%, specificity = 95%, P <10(-82) for IC vs all controls). HB-EGF levels were also significantly lower and EGF levels significantly higher in IC urine than in specimens from controls (P <10(-84) and P <10(-36), respectively). These findings confirm the utility of APF, HB-EGF, and EGF as markers for IC. Understanding the reasons for altered levels of these markers may lead to understanding the pathogenesis of this disorder.

UI MeSH Term Description Entries
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D006133 Growth Substances Signal molecules that are involved in the control of cell growth and differentiation. Mitogens, Endogenous,Endogenous Mitogens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D052776 Female Urogenital Diseases Pathological processes of the female URINARY TRACT and the reproductive system (GENITALIA, FEMALE). Female Genitourinary Diseases,Female Genitourinary Disease,Female Urogenital Disease,Genitourinary Disease, Female,Genitourinary Diseases, Female,Urogenital Disease, Female,Urogenital Diseases, Female
D052801 Male Urogenital Diseases Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE). Male Genitourinary Diseases,Genitourinary Disease, Male,Genitourinary Diseases, Male,Male Genitourinary Disease,Male Urogenital Disease,Urogenital Disease, Male,Urogenital Diseases, Male
D018856 Cystitis, Interstitial A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency. Cystitis, Chronic Interstitial,Interstitial Cystitis,Bladder Pain Syndrome,Chronic Interstitial Cystitis,Interstitial Cystitis, Chronic,Painful Bladder Syndrome,Bladder Pain Syndromes,Chronic Interstitial Cystitides,Cystitides, Chronic Interstitial,Cystitides, Interstitial,Interstitial Cystitides,Interstitial Cystitides, Chronic,Pain Syndrome, Bladder

Related Publications

S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
February 2009, BJU international,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
September 2019, Clinical chemistry and laboratory medicine,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
July 2020, Reproduction (Cambridge, England),
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
May 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
January 2008, Advances in experimental medicine and biology,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
April 2016, Cancer biotherapy & radiopharmaceuticals,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
May 2006, Cancer science,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
June 2001, Urology,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
July 2008, Journal of pediatric gastroenterology and nutrition,
S K Keay, and C O Zhang, and J Shoenfelt, and D R Erickson, and K Whitmore, and J W Warren, and R Marvel, and T Chai
October 2012, The Journal of surgical research,
Copied contents to your clipboard!